Hypoparathyroidism

Hypoparathyroidism is an endocrine disorder in which the parathyroid glands produce insufficient parathyroid hormone (PTH), resulting in dangerously low blood calcium (hypocalcemia) and elevated phosphate (hyperphosphatemia). Without adequate PTH signaling, the body cannot maintain the calcium balance essential for muscle contraction, nerve conduction, and cardiac rhythm. Understanding its causes, recognizing its distinctive physical signs, and managing it carefully long-term can prevent life-threatening complications.

Table of Contents

  1. What is Hypoparathyroidism?
  2. Causes and Risk Factors
  3. Signs and Symptoms
  4. Chvostek and Trousseau Signs
  5. Diagnosis
  6. Acute Management
  7. Long-Term Treatment
  8. Hypomagnesemia as a Reversible Cause
  9. Research Papers
  10. Connections
  11. Featured Videos

What is Hypoparathyroidism?

Hypoparathyroidism occurs when the parathyroid glands — four tiny glands embedded in or near the thyroid — fail to secrete adequate amounts of PTH. This hormone is the master regulator of calcium homeostasis, and its absence creates a cascade of metabolic problems.

Under normal conditions, PTH raises serum calcium through three coordinated mechanisms:

  1. Bone resorption: PTH activates osteoclasts, releasing calcium and phosphate from the skeletal matrix into the bloodstream.
  2. Renal calcium reabsorption: PTH stimulates the distal convoluted tubule of the kidney to reabsorb calcium that would otherwise be lost in urine.
  3. Vitamin D activation: PTH upregulates renal 1-alpha-hydroxylase, the enzyme that converts 25-hydroxyvitamin D into the active form, 1,25-dihydroxyvitamin D (calcitriol). Calcitriol in turn increases intestinal calcium absorption.

When PTH is absent or severely reduced, all three mechanisms fail simultaneously. Blood calcium falls, phosphate rises (because PTH normally promotes renal phosphate excretion), and the kidney cannot activate vitamin D. The result is a dangerous state of neuromuscular hyperexcitability that can progress to tetany, seizures, and cardiac arrhythmias.

Hypoparathyroidism is classified as one of the few remaining endocrine hormone-deficiency diseases without a widely available hormone-replacement standard of care — until recently, PTH itself was not a practical treatment option.

Back to Table of Contents

Causes and Risk Factors

The causes of hypoparathyroidism range from surgical complications to genetic disorders to nutritional deficiencies.

Surgical Hypoparathyroidism (~75% of cases)

The most common cause is inadvertent removal or devascularization of the parathyroid glands during thyroid or parathyroid surgery. Because the parathyroid glands are small (each roughly the size of a grain of rice) and anatomically variable, they are at significant risk during neck surgery. Transient hypoparathyroidism is common after total thyroidectomy and usually resolves within weeks as traumatized glands recover. Permanent surgical hypoparathyroidism occurs when gland function does not return after six months.

Autoimmune Hypoparathyroidism

Isolated autoimmune destruction of the parathyroid glands can occur, or it may present as part of Autoimmune Polyglandular Syndrome Type 1 (APS-1), caused by mutations in the AIRE gene on chromosome 21q22. APS-1 presents in childhood with the triad of hypoparathyroidism, primary adrenal insufficiency, and chronic mucocutaneous candidiasis. Anti-CaSR (calcium-sensing receptor) antibodies have also been identified in some autoimmune cases.

Genetic and Developmental Causes

Other Causes

Back to Table of Contents

Signs and Symptoms

Symptoms arise primarily from hypocalcemia-induced neuromuscular irritability, though chronic disease produces distinct structural changes. The severity correlates with the degree and rate of calcium decline — a rapidly falling calcium is more symptomatic than a chronically low but stable level.

Neuromuscular Symptoms

Cardiac Symptoms

Chronic and Structural Changes

Back to Table of Contents

Chvostek and Trousseau Signs

Two classic bedside signs are used to detect latent (subclinical) tetany in patients with suspected hypocalcemia. Both reflect the increased excitability of peripheral nerves when extracellular calcium is low.

Chvostek Sign

To elicit the Chvostek sign, the examiner taps the facial nerve as it exits the parotid gland, approximately 2 cm anterior to the tragus of the ear. A positive result is ipsilateral twitching of the facial muscles — ranging from a subtle twitch of the corner of the mouth to contraction of the entire half of the face in severe hypocalcemia.

Sensitivity and specificity: The Chvostek sign is sensitive but not specific. It is present in 10–25% of normocalcemic individuals and can be absent even in proven hypocalcemia. It should never be used as the sole diagnostic criterion.

Trousseau Sign

The Trousseau sign is elicited by inflating a blood pressure cuff on the upper arm to 20 mmHg above the patient's systolic blood pressure and maintaining it for 3 minutes. Occlusion of the brachial artery creates local ischemia and hypocalcemia, which provokes carpopedal spasm in a susceptible patient — the hand assumes a characteristic posture with wrist flexion, finger extension at the metacarpophalangeal joints, and thumb adduction (the "accoucheur's hand").

Sensitivity and specificity: The Trousseau sign is more specific than the Chvostek sign for true hypocalcemia. It is positive in approximately 94% of hypocalcemic patients and in only 1% of normocalcemic individuals. It is the preferred bedside test when hypocalcemia is clinically suspected.

Both signs are most useful for identifying patients at risk for symptomatic tetany before full-blown symptoms develop, particularly in the postoperative setting after thyroid or parathyroid surgery.

Back to Table of Contents

Diagnosis

The biochemical diagnosis of hypoparathyroidism is straightforward once the clinician measures the right panel of tests. The key diagnostic triad is: low calcium + low PTH + high phosphate.

Core Laboratory Tests

Differentiating from Pseudohypoparathyroidism

Pseudohypoparathyroidism (PHP) presents with identical biochemistry (low calcium, high phosphate, high PTH) but the cause is end-organ resistance to PTH action rather than PTH deficiency. PHP type 1a is associated with Albright's hereditary osteodystrophy (short stature, obesity, short fourth metacarpal, round face). PTH levels are elevated (not low), distinguishing it from true hypoparathyroidism.

Imaging

CT of the brain may reveal basal ganglia calcifications in chronic disease. ECG should be obtained to assess QT interval. Renal ultrasound or CT is warranted in patients with longstanding disease or when nephrocalcinosis/nephrolithiasis is suspected.

Back to Table of Contents

Acute Management

Acute symptomatic hypocalcemia — presenting with tetany, seizures, laryngospasm, or QT prolongation — is a medical emergency requiring prompt intravenous calcium replacement.

Intravenous Calcium Gluconate

The preferred IV preparation is calcium gluconate (not calcium chloride, which is more irritating and causes tissue necrosis if extravasated). The standard acute protocol:

  1. Bolus: 1–2 grams of calcium gluconate (10–20 mL of 10% solution) infused over 10–20 minutes, with continuous cardiac monitoring. Too rapid an infusion can cause vasodilation, hypotension, or cardiac arrhythmia.
  2. Maintenance infusion: follow the bolus with a continuous infusion of 0.5–1.5 mg elemental calcium per kg per hour, typically in D5W or normal saline, titrated to keep ionized calcium in the low-normal range (1.0–1.12 mmol/L).
  3. Avoid overcorrection: targeting a serum calcium above 9 mg/dL without PTH action leads to marked hypercalciuria and rapid stone formation.

Cardiac Monitoring

All patients receiving IV calcium should be on continuous cardiac telemetry. The QT interval typically normalizes within hours of calcium repletion. Hypomagnesemia prolongs QT through independent mechanisms and must be corrected simultaneously.

Correct Hypomagnesemia First

If serum magnesium is below 0.7 mmol/L, administer IV magnesium sulfate before or alongside calcium. Hypocalcemia refractory to calcium replacement is almost always due to unrecognized hypomagnesemia. PTH secretion is magnesium-dependent — the signaling pathway cannot function without adequate intracellular magnesium.

Transition to Oral Therapy

Once symptomatic control is achieved and the patient can tolerate oral medications, transition to calcitriol plus oral calcium supplements (see Long-Term Treatment below). Abrupt discontinuation of IV calcium before adequate oral supplementation leads to rebound hypocalcemia.

Back to Table of Contents

Long-Term Treatment

Long-term management of hypoparathyroidism focuses on maintaining serum calcium in a safe range while minimizing the complications of therapy — primarily hypercalciuria, nephrolithiasis, and nephrocalcinosis that result from treating hypocalcemia without PTH's renal calcium-conserving effect.

Calcitriol (Active Vitamin D)

Calcitriol (1,25-dihydroxyvitamin D3) is the cornerstone of long-term therapy. Because PTH is absent, the kidney cannot activate vitamin D — therefore only the already-active form (calcitriol) is effective. Ergocalciferol or cholecalciferol alone are insufficient.

Calcium Supplements

Oral elemental calcium (1,000–1,500 mg/day in divided doses) is taken with calcitriol:

Serum Calcium Targets

Target serum total calcium in the low-normal range: 8.0–8.5 mg/dL. This is deliberately below the middle of the reference range (8.5–10.5 mg/dL) because without PTH-driven renal calcium reabsorption, any increment in serum calcium is filtered freely by the kidney, leading to hypercalciuria. Keeping calcium at 8.0–8.5 mg/dL maintains symptom control while limiting urinary calcium excretion.

Hydrochlorothiazide

Thiazide diuretics reduce urinary calcium excretion by promoting proximal tubular reabsorption. Adding hydrochlorothiazide (12.5–50 mg/day) allows higher calcitriol and calcium supplementation doses in patients who develop hypercalciuria or nephrolithiasis despite conservative targets.

Recombinant PTH (Natpara, rhPTH[1-84])

In 2015, the FDA approved recombinant human PTH(1-84) (brand name Natpara) for adults with hypoparathyroidism inadequately controlled with conventional therapy. Administered by daily subcutaneous injection, it reduces calcitriol and calcium supplement requirements, better mimics physiological PTH action (including renal calcium conservation), and is associated with improved quality of life in clinical trials. It carries a boxed warning for osteosarcoma risk (seen in rodent studies at supratherapeutic doses) and is available only through a restricted program (REMS).

Monitoring Schedule

Back to Table of Contents

Hypomagnesemia as a Reversible Cause

Hypomagnesemia is one of the most commonly overlooked and most important reversible causes of functional hypoparathyroidism. Understanding this relationship can spare patients from a lifelong diagnosis of permanent hypoparathyroidism when the true problem is correctable magnesium deficiency.

The Mechanism

Magnesium plays a dual role in parathyroid function:

  1. PTH secretion: The parathyroid cell releases PTH via a magnesium-dependent exocytosis process. Intracellular magnesium is required for G-protein signaling downstream of the calcium-sensing receptor. When magnesium is severely depleted, this signaling fails and PTH secretion is suppressed regardless of how low serum calcium drops.
  2. Peripheral PTH resistance: Even if some PTH is secreted, target tissues (kidney and bone) cannot respond normally to PTH without adequate magnesium, because the adenylate cyclase cascade that PTH activates is also magnesium-dependent. This creates end-organ resistance identical to pseudohypoparathyroidism.

Common Causes of Hypomagnesemia

Clinical Rule

Always check and correct serum magnesium before diagnosing permanent hypoparathyroidism. If serum magnesium is below 0.7 mmol/L (1.7 mg/dL), replete with IV magnesium sulfate (2–4 g over 2–4 hours), then recheck PTH and calcium 24–48 hours later. In true hypomagnesemia-induced functional hypoparathyroidism, PTH and calcium normalize after magnesium repletion — no further treatment is needed. This diagnostic step is especially critical in patients with alcohol use disorder admitted for any reason, as hypomagnesemia-induced tetany is common and easily corrected.

Oral Magnesium for Maintenance

Once the acute deficit is corrected, identify and treat the underlying cause. Where ongoing losses are unavoidable (e.g., persistent PPI use, loop diuretics), oral magnesium supplementation (magnesium glycinate or malate; 200–400 mg elemental magnesium daily) helps maintain levels. Magnesium oxide is poorly absorbed and should be avoided. Monitor stool tolerance — magnesium has a dose-dependent laxative effect.

Back to Table of Contents

Research Papers

Key peer-reviewed studies and guidelines on hypoparathyroidism:

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents